title: Behavioral recovery following sub-chronic paeoniflorin administration in the striatal 6-OHDA lesion rodent model of Parkinson's disease.
abstract: In the present studies, the effect of paeoniflorin (PF), one of the main compounds extracted from Paeoniae radix, in alleviating the neurological impairment following unilateral striatal 6-hydroxydopamine (6-OHDA) lesion was examined in Sprague-Dawley rats. Sub-chronic PF (2.5, 5 and 10 mg/kg, s.c., twice daily for 11 days) administration dose-dependently reduced apomorphine (APO)-induced rotation, suggesting that PF had an ameliorative effect on the 6-OHDA-induced neurological impairment. Notably, PF had no direct action on dopamine D(1) receptor or dopamine D(2) receptor indicated by the competitive binding experiments. These results suggest that PF, an active component of Paeoniae radix, might provide an opportunity to introduce a non-dopaminergic management of Parkinson's disease.
authors: Department of Pharmacology II, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China.
authors: Da-Zhi
authors: DZ
authors: Liu
authors: Jun
authors: J
authors: Zhu
authors: Dao-Zhong
authors: DZ
authors: Jin
authors: Li-Min
authors: LM
authors: Zhang
authors: Xin-Quan
authors: XQ
authors: Ji
authors: Yang
authors: Y
authors: Ye
authors: Chun-Ping
authors: CP
authors: Tang
authors: Xing-Zu
authors: XZ
authors: Zhu
mesh_terms: D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001552:Benzazepines / Q000378:metabolism; D001565:Benzoates / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D001667:Binding, Competitive / Q000187:drug effects; D001952:Bridged-Ring Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000378:metabolism; D005960:Glucosides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D006892:Hydroxydopamines; D066298:In Vitro Techniques; D008297:Male; D008566:Membranes / Q000187:drug effects / Q000378:metabolism; D008845:Microinjections; D039821:Monoterpenes; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology*; D020891:Raclopride / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013239:Stereotyped Behavior / Q000187:drug effects; D006027:Glycosides
chemical_list: D001058:Apomorphine; D001552:Benzazepines; D001565:Benzoates; D001952:Bridged-Ring Compounds; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D005960:Glucosides; D006892:Hydroxydopamines; D039821:Monoterpenes; D020891:Raclopride; C015423:peoniflorin; D006027:Glycosides